• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Alterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM).
CONCLUSIONS: Alterations in BAP1 in MPM were a negative predictor for response to chemotherapy and could possibly be used as a companion biomarker for treatment decision. PMID: 33547197 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2021 Category: Cancer & Oncology Authors: Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, Felley-Bosco E, Wollscheid B, Bankov K, Demes MC, Opitz I, Wild PJ Tags: Clin Cancer Res Source Type: research

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Conclusions: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine. PMID: 31533931 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 17, 2019 Category: Cancer & Oncology Authors: Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, Zhang Y, Zhang JS, Wang E, Dutta SK, Schmitt DM, Giles FJ, Kozikowski AP, Mazar AP, Mukhopadhyay D, Billadeau DD Tags: Clin Cancer Res Source Type: research

Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response. PMID: 29463559 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 20, 2018 Category: Cancer & Oncology Authors: Marangoni E, Laurent C, Coussy F, El Botty R, Chateau-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Némati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noël A, Salomon A, Lae M, Decaudin D, Roman-Roman S, B Tags: Clin Cancer Res Source Type: research

Biased Expression of the FOXP3 Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
CONCLUSIONS: (i) Biased expression of the FOXP3Δ3 isoform in bladder cancer inversely correlates with overall survival, (ii) FOXP3Δ3 induces a unique gene program that mediates cancer differentiation, and (iii) FOXP3Δ3 may augment chemotherapy resistance. Clin Cancer Res; 22(21); 5349-61. ©2016 AACR. PMID: 27189164 [PubMed - in process]
Source: Clinical Cancer Research - October 31, 2016 Category: Cancer & Oncology Authors: Zhang H, Prado K, Zhang KX, Peek EM, Lee J, Wang X, Huang J, Li G, Pellegrini M, Chin AI Tags: Clin Cancer Res Source Type: research

Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
CONCLUSIONS: Hypomethylation of CpG sites within the MSX1 gene is associated with resistant HGSOC disease at presentation and identifies expression of MSX1 as conferring platinum drug sensitivity. PMID: 26763252 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 13, 2016 Category: Cancer & Oncology Authors: Bonito NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, Brown R Tags: Clin Cancer Res Source Type: research

VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
Conclusion: Our results suggest that VEGF/VEGFR-2 pathway plays a role in regulation of EZH2 expression via E2F3, HIF-1α and miR-101. EZH2 depletion decreases the malignant potential of lung adenocarcinoma and sensitivity of the cells to both platinum-based and VEGFR-2-targeted therapy. PMID: 24850841 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 21, 2014 Category: Cancer & Oncology Authors: Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson M, Simon G, Wang J, Coombes K, Lee JJ, Hong WK, Heymach JV, Minna JD, Wistuba II Tags: Clin Cancer Res Source Type: research

Reduced expression of microRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Conclusion Our findings indicate that microRNA-27a negatively regulates SLC7A11 in cisplatin-resistant bladder cancer, and shows promise as a marker for patients likely to benefit from cisplatin-based chemotherapy. SLC7A11 inhibition with sulfasalazine may be a promising therapeutic approach to the treatment of cisplatin-resistant disease. PMID: 24516043 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 10, 2014 Category: Cancer & Oncology Authors: Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, Catto JW Tags: Clin Cancer Res Source Type: research

Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: an Optimal Delivery of siRNA and Anticancer Drug.
CONCLUSION: We show a high therapeutic potential for combinatorial treatment of ovarian carcinoma with a novel drug delivery system that effectively transports siRNA targeting to CD44 mRNA simultaneously with cytotoxic agents. PMID: 24036854 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 13, 2013 Category: Cancer & Oncology Authors: Shah V, Taratula O, G OB, Taratula OR, Rodriguez-Rodriguez L, Minko T Tags: Clin Cancer Res Source Type: research

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
CONCLUSION: These results strongly support investigation of ganetespib, a single-targeted agent with effects on numerous proteins and pathways, in augmenting standard EOC therapies. PMID: 23900136 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 30, 2013 Category: Cancer & Oncology Authors: Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov IA, Martin L, Litwin S, Proia DA, Golemis EA, Connolly DC Tags: Clin Cancer Res Source Type: research

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer. PMID: 23386691 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research